Evans Syndrome Market Research Report - Global Forecast till 2027

Evans syndrome Market Information: by diagnosis (blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry), treatment (Splenectomy, Pharmacologic, Biologic therapy, Stem Cell), end user – Global forecast till 2027

ID: MRFR/LS/3700-HCR | | Region: Global | 85 pages

Market Scenario


Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.


According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common category of disease in the United States after heart disease and cancer. It is reported that it affects approximately 5%–8% of the population i.e. 14–22 million persons.


The severity and symptoms of Evans syndrome vary greatly from one person to another. Some patients with Evans syndrome may first show the high destruction of red blood cells (RBCs), known as anemia, and others may first show low levels of platelets, known as thrombocytopenia. Low levels of white blood cells (WBSs), known as neutropenia, is less common in individuals with Evans syndrome than thrombocytopenia or anemia.


Notably, growing public awareness is the key factor driving the Evans syndrome market. Nowadays, people are becoming more aware of the different types of autoimmune disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and conscious of the diseases. Thus, increasing awareness has provided a push to the growth of the market.


Various other factors such as increasing incidents of autoimmune disorders, increasing government assistance, improving regulatory framework, increasing automation of laboratories and rising funding and reimbursement are continuously contributing to the growth of the global Evans syndrome market.


Despite these drivers, there are some issues associated with Evans syndrome market. Some of the challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.


It is estimated that the Evans syndrome market is expected to grow at a CAGR 10.2% during the forecast period of 2017-2023.


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


Segmentation


The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and distribution channels.


On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells, and others. The blood test is further segmented into complete blood count (CBC), and direct antiglobulin test.


On the basis of the treatment, the market is classified as pharmacologic therapy, splenectomy,


Biologic therapy, stem cell transplantation, and others. The pharmacologic therapy is further segmented into Prednisone and intravenous immunoglobulin (IVIg) therapy. The biologic therapy is segmented into Rituximab and others.


On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.


Regional Analysis


The Americas dominate the Evans syndrome market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.


Europe holds the second position in the Evans syndrome market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.


Asia Pacific is the fastest growing Evans syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.


The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.


Key Players


Some of key the players in the global Evans syndrome market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, and Others.


Research Methodology Evans Syndrome Market


Sources: Annual reports, Press release, White paper, and Company presentation



Frequently Asked Questions (FAQ) :


Evans syndrome market is projected to grow at a 10.2% CAGR between 2017-2023.

The Americas is expected to dominate the evans syndrome market.

Splenectomy, stem cell transplantation, biologic therapy, pharmacologic therapy, and others are the different types of treatment for evans syndrome.

Growing awareness and rising prevalence of autoimmune disorders are the key factors driving the evans syndrome market.

Key players profiled in the evans syndrome market include ChemoMetec A/S, BD, Eli Lily and Company, Abbott Laboratories, Sigma-Aldrich, Bayer AG, Enzon Pharmaceuticals, Inc., Novartis AG, Novartis AG, GlaxoSmithKline plc, Astellas Pharma, Inc., Sanofi, Merck & Co., Pfizer, and others.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Evans Syndrome Market, by Diagnosis

6.1 Introduction

6.2 Blood Test

6.2.1 Market Estimates & Forecast, 2020 – 2023

6.3 Bone Marrow Biopsy

6.3.1 Market Estimates & Forecast, 2020 – 2023

6.4 Antibody Assays

6.4.1 Market Estimates & Forecast, 2020 – 2023

6.5 Computed Tomography (CT) Scan

6.5.1 Market Estimates & Forecast, 2020 – 2023

6.6 Flow Cytometery of double-negative T cells

6.6.1 Market Estimates & Forecast, 2020 – 2023

Chapter 7. Global Evans Syndrome Market, by treatment

7.1 Introduction

7.2 Pharmacologic Therapy

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Splenectomy

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Biologic therapy

7.4.1 Market Estimates & Forecast, 2020-2027

7.5 Stem Cell Transplantation

7.5.1 Market Estimates & Forecast, 2020-2027

Chapter 8. Global Evans Syndrome Market, by Distribution Channel

8.1 Introduction

8.2 Hospitals

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Clinics

8.3.2 Market Estimates & Forecast, 2020-2027

8.4 Diagnostic Centers

8.4.1 Market Estimates & Forecast, 2020-2027

8.5 Drug Stores

8.5.2 Market Estimates & Forecast, 2020-2027

8.6 Pharmacies

8.6.2 Market Estimates & Forecast, 2020-2027

8.7 Others

8.7.2 Market Estimates & Forecast, 2020-2027

Chapter 9. Global Evans Syndrome Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Pfizer

11.1.1 Company Overview

11.1.2 Type of Causative Agents Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Merck & Co.

11.2.1 Company Overview

11.2.2 Type of Causative Agents Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Sanofi

11.3.1 Company Overview

11.3.2 Type of Causative Agents Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Astellas Pharma, Inc.

11.4.1 Company Overview

11.4.2 Type of Causative Agents/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 GlaxoSmithKline plc

11.5.1 Company Overview

11.5.2 Type of Causative Agents Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Novartis AG

11.6.1 Company Overview

11.6.2 Type of Causative Agents Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 BD

11.7.1 Overview

11.7.2 Type of Causative Agents Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Evans Syndrome Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Evans Syndrome Industry Synopsis, 2020-2027

Table 2 Evans Syndrome Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Evans Syndrome Market by Region, 2020-2027, (USD Million)

Table 4 Evans Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 6 Evans Syndrome Market by Distribution Channels, 2020-2027, (USD Million)

Table 7 North America Evans Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Evans Syndrome Market by Distribution Channels, 2020-2027, (USD Million)

Table 10 US Evans Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 11 US Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 12 US Evans Syndrome Market by Distribution Channels, 2020-2027, (USD Million)

Table 13 Canada Evans Syndrome market by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Evans Syndrome market by Distribution Channels, 2020-2027, (USD Million)

Table 16 South America Evans Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Evans Syndrome Market by Distribution Channels, 2020-2027, (USD Million)

Table 19 Europe Evans Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Evans Syndrome Market by Distribution Channels, 2020-2027, (USD Million)

Table 22 Western Europe Evans Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Evans Syndrome Market by Distribution Channels, 2020-2027, (USD Million)

Table 25 Eastern Europe Evans Syndrome market by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Evans Syndrome Market by Distribution Channels, 2020-2027, (USD Million)

Table 28 Asia Pacific Evans Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia Pacific Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Evans Syndrome market by Distribution Channels, 2020-2027, (USD Million)

Table 31 Middle East & Africa Evans Syndrome Market by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa Evans Syndrome Market by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Evans Syndrome market by Distribution Channels, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Evans Syndrome Market

Figure 3 Segmentation Market Dynamics for Evans Syndrome Market

Figure 4 Global Evans Syndrome market Share, by Diagnosis 2020

Figure 5 Global Evans Syndrome market Share, by Treatment 2020

Figure 6 Global Evans Syndrome market Share, by Distribution Channels, 2020

Figure 7 Global Evans Syndrome market Share, by Region, 2020

Figure 8 North America Evans Syndrome market Share, by Country, 2020

Figure 9 Europe Evans Syndrome market Share, by Country, 2020

Figure 10 Asia Pacific Evans Syndrome market Share, by Country, 2020

Figure 11 Middle East & Africa Evans Syndrome market Share, by Country, 2020

Figure 12 Global Evans Syndrome market: Company Share Analysis, 2020 (%)

Figure 13 Pfizer: Key Financials

Figure 14 Pfizer Segmental Revenue

Figure 15 Pfizer: Geographical Revenue

Figure 16 Merck & Co.: Key Financials

Figure 17 Merck & Co.: Segmental Revenue

Figure 18 Merck & Co.: Geographical Revenue

Figure 19 Sanofi: Key Financials

Figure 20 Sanofi: Segmental Revenue

Figure 21 Sanofi: Geographical Revenue

Figure 22 Astellas Pharma, Inc.: Key Financials

Figure 23 Astellas Pharma, Inc.: Segmental Revenue

Figure 24 Astellas Pharma, Inc.: Geographical Revenue

Figure 25 GlaxoSmithKline plc: Key Financials

Figure 26 GlaxoSmithKline plc: Segmental Revenue

Figure 27 GlaxoSmithKline plc Geographical Revenue

Figure 28 Novartis AG: Key Financials

Figure 29 Novartis AG: Segmental Revenue

Figure 30 Novartis AG: Geographical Revenue

Figure 31 BD: Key Financials

Figure 32 BD: Segmental Revenue

Figure 33 BD: Geographical Revenue